Fuady Ahmad, Houweling Tanja A, Mansyur Muchtaruddin, Richardus Jan H
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Acta Med Indones. 2018 Jan;50(1):3-10.
Indonesia is the second-highest country for tuberculosis (TB) incidence worldwide. Hence, it urgently requires improvements and innovations beyond the strategies that are currently being implemented throughout the country. One fundamental step in monitoring its progress is by preparing a validated tool to measure total patient costs and catastrophic total costs. The World Health Organization (WHO) recommends using a version of the generic questionnaire that has been adapted to the local cultural context in order to interpret findings correctly. This study is aimed to adapt the Tool to Estimate Patient Costs questionnaire into the Indonesian context, which measures total costs and catastrophic total costs for tuberculosis-affected households.
the tool was adapted using best-practice guidelines. On the basis of a pre-test performed in a previous study (referred to as Phase 1 Study), we refined the adaptation process by comparing it with the generic tool introduced by the WHO. We also held an expert committee review and performed pre-testing by interviewing 30 TB patients. After pre-testing, the tool was provided with complete explanation sheets for finalization.
seventy-two major changes were made during the adaptation process including changing the answer choices to match the Indonesian context, refining the flow of questions, deleting questions, changing some words and restoring original questions that had been changed in Phase 1 Study. Participants indicated that most questions were clear and easy to understand. To address recall difficulties by the participants, we made some adaptations to obtain data that might be missing, such as tracking data to medical records, developing a proxy of costs and guiding interviewers to ask for a specific value when participants were uncertain about the estimated market value of property they had sold.
the adapted Tool to Estimate Patient Costs in Bahasa Indonesia is comprehensive and ready for use in future studies on TB-related catastrophic costs and is suitable for monitoring progress to achieve the target of the End TB Strategy.
印度尼西亚是全球结核病发病率第二高的国家。因此,该国迫切需要在目前全国实施的策略之外进行改进和创新。监测其进展的一个基本步骤是准备一个经过验证的工具来衡量患者的总费用和灾难性总费用。世界卫生组织(WHO)建议使用已根据当地文化背景进行调整的通用问卷版本,以便正确解读研究结果。本研究旨在将“患者费用估算工具”问卷调整为适合印度尼西亚国情的版本,该问卷用于衡量结核病患者家庭的总费用和灾难性总费用。
该工具采用最佳实践指南进行调整。基于先前一项研究(称为第一阶段研究)中进行的预测试,我们通过将其与WHO推出的通用工具进行比较来完善调整过程。我们还召开了专家委员会评审会议,并通过采访30名结核病患者进行了预测试。预测试后,为该工具提供了完整的解释说明以完成定稿。
在调整过程中进行了72项主要更改,包括更改答案选项以符合印度尼西亚国情、完善问题流程、删除问题、更改一些措辞以及恢复在第一阶段研究中已更改的原始问题。参与者表示大多数问题清晰易懂。为了解决参与者的回忆困难问题,我们进行了一些调整以获取可能缺失的数据,例如追溯医疗记录数据、制定费用替代指标以及指导访谈员在参与者对其出售财产的估计市场价值不确定时询问具体数值。
经过调整的印度尼西亚语版“患者费用估算工具”全面且可用于未来有关结核病相关灾难性费用的研究,适用于监测实现终止结核病战略目标的进展情况。